Issue Highlights Clinical Gastroenterology and Hepatology Charles Kahi  Clinical Gastroenterology and Hepatology  Volume 14, Issue 11, Pages 1513-1515 (November 2016) DOI: 10.1016/j.cgh.2016.08.033 Copyright © 2016 AGA Institute Terms and Conditions

Figure 1 Subgroup analysis: sensitivity of second- vs first-generation systems for polyps ≥6 mm (A) and ≥10 mm (B). Events, TPs ([true positives], ie, patients with polyps ≥6 mm [A] or ≥10 mm [B]) found at CCE; Total, TPs at the reference standard (colonoscopy). Proportion, percentage of TPs found at CCE among patients with endoscopically proven polyps ≥6 mm (A) or ≥10 mm (B). Clinical Gastroenterology and Hepatology 2016 14, 1513-1515DOI: (10.1016/j.cgh.2016.08.033) Copyright © 2016 AGA Institute Terms and Conditions

Figure 2 Receiver operator characteristic curves for our scoring system for severe LGIB in derivation and validation cohorts. Clinical Gastroenterology and Hepatology 2016 14, 1513-1515DOI: (10.1016/j.cgh.2016.08.033) Copyright © 2016 AGA Institute Terms and Conditions

Figure 3 Outcome measures at week 14 for vedolizumab therapy in patients with (A) Crohn’s disease and (B) ulcerative colitis. *P value less than .005 when comparing week 6 and week 14 efficacy results. Clinical Gastroenterology and Hepatology 2016 14, 1513-1515DOI: (10.1016/j.cgh.2016.08.033) Copyright © 2016 AGA Institute Terms and Conditions